FTB Advisors Inc. Buys 200 Shares of Astrazeneca PLC (AZN)
FTB Advisors Inc. raised its stake in Astrazeneca PLC (NYSE:AZN) by 3.2% during the second quarter, according to its most recent disclosure with the SEC. The fund owned 6,471 shares of the company’s stock after buying an additional 200 shares during the quarter. FTB Advisors Inc.’s holdings in Astrazeneca PLC were worth $197,000 as of its most recent SEC filing.
A number of other hedge funds also recently bought and sold shares of the business. Garrison Financial Corp lifted its stake in Astrazeneca PLC by 0.5% in the second quarter. Garrison Financial Corp now owns 18,058 shares of the company’s stock valued at $616,000 after buying an additional 86 shares during the last quarter. Dorsey & Whitney Trust CO LLC lifted its stake in Astrazeneca PLC by 0.7% in the second quarter. Dorsey & Whitney Trust CO LLC now owns 13,315 shares of the company’s stock valued at $454,000 after buying an additional 94 shares during the last quarter. NEXT Financial Group Inc lifted its stake in Astrazeneca PLC by 1.8% in the second quarter. NEXT Financial Group Inc now owns 6,463 shares of the company’s stock valued at $220,000 after buying an additional 115 shares during the last quarter. Atria Investments LLC lifted its stake in Astrazeneca PLC by 0.5% in the second quarter. Atria Investments LLC now owns 24,695 shares of the company’s stock valued at $842,000 after buying an additional 129 shares during the last quarter. Finally, Financial Counselors Inc. lifted its stake in Astrazeneca PLC by 2.7% in the second quarter. Financial Counselors Inc. now owns 6,871 shares of the company’s stock valued at $234,000 after buying an additional 182 shares during the last quarter. Institutional investors own 14.17% of the company’s stock.
A number of research firms have issued reports on AZN. Barclays PLC reiterated an “overweight” rating on shares of Astrazeneca PLC in a research note on Monday, July 3rd. Sanford C. Bernstein reiterated a “buy” rating on shares of Astrazeneca PLC in a research note on Friday, September 22nd. Leerink Swann cut Astrazeneca PLC from an “outperform” rating to a “market perform” rating and cut their target price for the company from $36.00 to $31.00 in a research note on Thursday, July 27th. BNP Paribas upgraded Astrazeneca PLC from a “neutral” rating to an “outperform” rating in a research note on Monday, September 25th. Finally, Zacks Investment Research cut Astrazeneca PLC from a “strong-buy” rating to a “sell” rating in a research note on Monday, July 17th. Four research analysts have rated the stock with a sell rating, eleven have given a hold rating and fourteen have assigned a buy rating to the company’s stock. The company has an average rating of “Hold” and an average price target of $34.35.
Shares of Astrazeneca PLC (NYSE AZN) traded up 0.09% during midday trading on Friday, reaching $34.26. 2,973,636 shares of the company’s stock traded hands. The firm has a market capitalization of $86.75 billion, a P/E ratio of 22.47 and a beta of 0.76. Astrazeneca PLC has a 52-week low of $25.55 and a 52-week high of $35.60. The stock’s 50 day moving average price is $31.89 and its 200 day moving average price is $32.14.
Astrazeneca PLC (NYSE:AZN) last issued its quarterly earnings results on Thursday, July 27th. The company reported $0.87 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.41 by $0.46. Astrazeneca PLC had a return on equity of 35.90% and a net margin of 17.80%. The business had revenue of $5.05 billion for the quarter, compared to analyst estimates of $5.04 billion. During the same quarter in the prior year, the firm posted $0.83 earnings per share. The firm’s revenue for the quarter was down 9.9% compared to the same quarter last year. On average, equities research analysts anticipate that Astrazeneca PLC will post $1.91 EPS for the current fiscal year.
The company also recently declared a None dividend, which was paid on Monday, September 11th. Stockholders of record on Friday, August 11th were paid a dividend of $0.44 per share. This represents a dividend yield of 2.98%. The ex-dividend date was Wednesday, August 9th. Astrazeneca PLC’s dividend payout ratio (DPR) is presently 44.92%.
TRADEMARK VIOLATION WARNING: This report was published by The Cerbat Gem and is the property of of The Cerbat Gem. If you are accessing this report on another publication, it was stolen and republished in violation of international copyright & trademark laws. The original version of this report can be viewed at https://www.thecerbatgem.com/2017/10/08/ftb-advisors-inc-buys-200-shares-of-astrazeneca-plc-azn.html.
Astrazeneca PLC Profile
AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on discovery and development of products, which are then manufactured, marketed and sold. The Company focuses on three main therapy areas: Oncology, Cardiovascular & Metabolic Disease (CVMD) and Respiratory, while selectively pursuing therapies in Autoimmunity, Infection and Neuroscience.
Want to see what other hedge funds are holding AZN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Astrazeneca PLC (NYSE:AZN).
Receive News & Stock Ratings for Astrazeneca PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Astrazeneca PLC and related stocks with our FREE daily email newsletter.